Vitae
Founded 2023 · 1 employees on LinkedIn · 3 known investors
BetteRx is a pharmacy technology company that provides automated compounding systems and software to enable pharmacists to safely and efficiently prepare personalized, customized medications at scale while maintaining FDA compliance.
Also known as BetteRx · BetteRx Compounding Inc. · Vitae Industries
Founders & leadership
Vitae was founded in 2023 by Anthony Marsella and Daniel DeCiccio.
Investors · 3
Company profile
researched Aug 2026BetteRx Compounding Inc., formerly known as Vitae Industries, develops automation technology for pharmaceutical compounding — the preparation of prescription dosage forms tailored to individual patients. Its system, the AutoCompounder, is designed to let 503A compounding pharmacists produce personalized dosages with a three-step workflow: mixing the active pharmaceutical ingredient with dosage-form-specific inactive ingredients according to vetted formulas, loading the mixture into proprietary cartridges that clip into the machine, and then entering the drug, strengths and quantity for automated dispensing.
The company positions its technology as aligned with the requirements of the Drug Quality and Security Act, legislation enacted following the New England Compounding Center meningitis outbreak, and frames its objective as making personalized medication as accessible and scalable as generic drugs while maintaining safety and regulatory compliance. According to the company, BetteRx acquired Vitae Industries' technology.
Business model
The company supplies compounding automation systems, consumable cartridges and an associated compound formulary to pharmacies, which use the equipment in their own dispensing operations.
Traction
The company reports its system installed in 28 pharmacies nationwide, a formulary of over 300 compound APIs, and more than 500,000 doses dispensed by AutoCompounder units [0].
Latest developments
The business now operates under the name BetteRx Compounding Inc., having acquired the technology of Vitae Industries [0].
▸Full profile — market position, technology, go-to-market, geography
Market position
Operates in automated pharmaceutical compounding for personalized medicine, serving 503A compounding pharmacies under a regulatory framework shaped by the Drug Quality and Security Act [0].
The company emphasizes automation of an otherwise manual and time-consuming compounding process, a vetted formulary of over 300 APIs, and design intended to meet FDA and Drug Quality and Security Act standards [0][1].
Technology
The AutoCompounder automates the dispensing of compounded dosage forms. Compounds prepared from active pharmaceutical ingredients and dosage-form-specific inactive ingredients are loaded into cartridges that clip into the device; the operator specifies drug, strength(s) and quantity and the system produces the doses unattended. The company maintains a formulary of more than 300 compound APIs [0].
Go-to-market
503A compounding pharmacies and compounding pharmacists in the United States.
Geography
United States; a directory listing places the company at 1 Richmond Sq, Providence, Rhode Island [1].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlap
Companies competing with Vitae for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $149.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 1
launches, deals, and filingsThe company's website states that BetteRx acquired Vitae Industries' technology and that BetteRx Compounding Inc. was formerly Vitae Industries.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Vitaevitaeindustries.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vitae do?
- BetteRx (formerly Vitae Industries) builds automated compounding technology that lets pharmacies produce personalized medication doses.
- Who founded Vitae?
- Vitae was founded by Anthony Marsella, Daniel DeCiccio in 2023.
- Who are Vitae's investors?
- Vitae's investors include Compound, Slater Technology Fund, Social Starts.